SCHEMBL1721089

SCHEMBL1721089

Cc1[nH]c(=O)c2cc(Cl)ccc2c1CN1CCN(CCO)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
MEN1 O00255 1/20 0.52
POLB P06746 1/20 0.52
KMT2A Q03164 1/20 0.52
TP53 P04637 1/20 0.48
KDM4E B2RXH2 4/20 0.47
HPGD P15428 2/20 0.47
RXFP1 Q9HBX9 1/20 0.46
ERAP1 Q9NZ08 1/20 0.46
HTR1A P08908 1/20 0.44
HTR7 P34969 1/20 0.44
HTR6 P50406 1/20 0.44
LMNA P02545 2/20 0.44
RAB9A P51151 1/20 0.42
GAA P10253 3/20 0.41
GLA P06280 1/20 0.41
P4HB P07237 1/20 0.41
PIM1 P11309 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719560 0.89 ALDH1A1 (0.55) ALDH1A1MEN1POLBKMT2AKDM4E
SCHEMBL1720551 0.87 KMT2A (0.67) ALDH1A1MEN1POLBKMT2AKDM4E
SCHEMBL1720816 0.86 RXFP1 (0.46) ALDH1A1MEN1KMT2ATP53KDM4E
SCHEMBL4078200 0.84 RXFP1 (0.45) ALDH1A1MEN1POLBKMT2AKDM4E
SCHEMBL1720263 0.84 ALDH1A1 (0.52) ALDH1A1MEN1POLBKMT2AKDM4E
SCHEMBL1720869 0.83 HSD17B10 (0.55) ALDH1A1MEN1POLBKMT2ATP53
Iodide SCHEMBL1720366 0.83 RXFP1 (0.44) ALDH1A1MEN1POLBKMT2AKDM4E
SCHEMBL1720790 0.82 ALDH1A1 (0.50) ALDH1A1MEN1POLBKMT2ATP53
SCHEMBL4070060 0.80 OPRM1 (0.51) ALDH1A1KDM4EHPGDHTR1AGAA
SCHEMBL1719551 0.80 CDC7 (0.52) ALDH1A1MEN1POLBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 ALDH1A1 169/4885MEN1 3125/4885POLB 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.